← Explore

Focused Ultrasound Platform for Investigating Therapeutic Neuromodulation Across the Human Hippocampus

Spencer T. Brinker, Frank Preiswerk, Phillip J. White, Timothy Y. Mariano, Nathan J. McDannold, Ellen J. Bubrick

Ultrasound in Medicine & Biology 2020 · 10.1016/j.ultrasmedbio.2020.01.007

human patientepilepsynone reported

Abstract

Pulsed low-intensity focused ultrasound (PLIFUS) has shown promise in inducing neuromodulation in several animal and human studies. Therefore, it is of clinical interest to develop experimental platforms to test repetitive PLIFUS as a therapeutic modality in humans with neurologic disorders. In the study described here, our aim was to develop a laboratory-built experimental device platform intended to deliver repetitive PLIFUS across the hippocampus in seizure onset zones of patients with drug-resistant temporal lobe epilepsy. The system uses neuronavigation targeting over multiple therapeutic sessions. PLIFUS (548 kHz) was emitted across multiple hippocampal targets in a human subject with temporal lobe epilepsy using a mechanically steered piezoelectric transducer. Stimulation was delivered up to 2.25 W/cm 2 spatial peak temporal average intensity (free-field equivalent), with 36%-50% duty cycle, 500-ms sonications and 7-s inter-stimulation intervals lasting 140 s per target and repeated for multiple sessions. A first-in-human PLIFUS course of treatment was successfully delivered using the device platform with no adverse events.

Abstract via europepmc.

Specieshuman
Subjects1 participants
Sessions per subjectnot reported
Randomisednot reported
Blindingnot reported
Sham / controlnone
Auditory controlnot reported
Readout timingnot reported
Anaesthesianot applicable
Readoutsnone reported
Direction of effectnot assessedThis technical note reports device delivery and safety only; no neuromodulatory outcome or seizure/EEG effect was assessed or reported for this first-in-human PLIFUS course.
Adverse eventsnone observedA first-in-human PLIFUS course of treatment was successfully delivered using the device platform with no adverse events.

Exposures

Exposure 1: PLIFUS to hippocampal targets (subject 1, TLE)

Target: hippocampus — “human hippocampus (multiple hippocampal targets, seizure onset zone)
Device: custom-built · Piezo Kinetics · PZT-4, 548 kHz spherically focused piezoceramic transducer

Pulse timing
Waveformpulsed
Fundamental frequency (kHz)548✓✓
Pulse duration (ms)not reported
Pulse repetition frequency (Hz)500✓✓
Duty cycle (%)36, 50swept✓✓
Sonication duration (s)0.5✓✓
Pressure and intensity, by domain
Free-field pressure (kPa)140, 320swept✓✓
Free-field Isppa (W/cm²)not reported
Free-field Ispta (W/cm²)0.5, 2.25swept✓✓
In-situ estimatenot reported
In-situ pressure (kPa)not reported
In-situ Isppa (W/cm²)not reported
In-situ Ispta (W/cm²)not reported
Protocol, in the paper’s words

140-s sonications emitted to each hippocampal target with 500-ms sonications repeated with 7-s inter-stimulation intervals, lasting 140 s per target; treatment repeated across multiple hippocampal targets (four targets) and repeated in biweekly therapy sessions for 3 weeks in subject 1 with TLE.

Flags from extraction

  • exposures[0].free_field.pressure_kpaRange (0.14-0.32 MPa) and Ispta range (0.5-2.25 W/cm2) are stated only in the Figure 1 caption, not in the Results text (which gives only the maximum, 0.32 MPa / 2.25 W/cm2); recorded here as the full stated range but flagged as figure-legend-sourced.
  • exposures[0].timing.pulse_duration_msOnly PRF (500 Hz) and duty cycle (36-50%) are stated for the internal pulsing within the 500-ms sonication; no explicit pulse/cycle count is given to state a pulse duration, so left not_reported rather than computed.
  • exposures[0].timing.duty_cycle_pctText and figure caption both give duty cycle as "36% 50%"; likely an en-dash lost in OCR representing a 36-50% range across sessions/targets, recorded as [36, 50].
  • n_sessions_per_subjectPaper states treatment was 'repeated in biweekly therapy sessions for 3 weeks' but never gives an explicit session count.